Posttraumatic Stress Disorder Author: Jeffrey P. Staab, MD, MS
Editorial changes - 2009-10-13
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Glossary
bid
twice daily
CI
confidence interval
CT
computed tomography
GABA
γ-aminobutyric acid
GI
gastrointestinal
HCA
heterocyclic antidepressant
MCEPS
Michigan Critical Events Perception Scale
MRI
magnetic resonance imaging
OTC
over the counter
PTSD
posttraumatic stress disorder
qd
once daily
qhs
every night
RR
relative risk
SF-36
Medical Outcomes Study 36-item Short-Form Health Survey
SSRI
selective serotonin-reuptake inhibitor
TCA
tricylcic antidepressant
TSH
thyrotropin
Jeffrey P. Staab, MD, MS, is a consultant for Eli Lilly, Forest Laboratories, received honorarium from Abbott Laboratories, received grants from GlaxoSmithKline, Pfizer. Michael Roy, MD, editorial consultant, received honorarium from PFizer.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.